Appendix 1: Proposal comment summary table

Respondent	Response to proposal	Details	Comment from Technology Appraisal
Bristol-Myers Squibb	Agree	First, the NICE assessment that no new evidence has been published to date that would affect previous guidance is correct [Commercial in confidence information removed]	Noted
British Infection Society	No objection		Noted
Gilead	No objection	In light of the comments made by the Institute I would like to consolidate on the importance of tenofovir disoproxil fumarate being included in the MTA. As you're aware tenofovir has now reached the FAD stage of the STA process and is due to receive a positive final guidance in a matter of weeks. Gilead welcome the opportunity to discuss a potential MTA in March 2010.	Noted
Royal College of Nursing	No objection		Noted
Royal College of Physicians	Agree		Noted
Roche	Agree		Noted
Royal College of Pathologists	Agree		Noted
Research Institute for the Care of Older People	No comment		Noted

No response received from:

Manufacturers/sponsors	General
 Novartis Pharmaceuticals UK 	Age Concern Cymru
(telbivudine)	Board of Community Health Councils in
 Schering-Plough (interferon alfa 2a, 	Wales
interferon alfa 2b)	British National Formulary
	Department of Health, Social Services
Patient/carer groups	and Public Safety for Northern Ireland
Afiya Trust	Medicines and Healthcare products
Age Concern England	Regulatory Agency
AVERT	 National Association of Primary Care
Black Health Agency	National Public Health Service for Wales
British Liver Trust	NHS Alliance
British Organ Donor Society	NHS Confederation

- British Viral Hepatitis Group
- Chinese National Healthy Living Centre
- Compass UK
- Confederation of Indian Organisations
- Counsel and Care
- Drugs Action
- Equalities National Council
- GMFA The Gay Men's Health Charity
- Haemophilia Alliance
- Haemophilia Society
- Help the Aged
- Hepatitis A -Z
- Hepatitis B Foundation UK
- Mainliners
- Muslim Council of Great Britain
- Muslim Health Network
- Positively Women
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Transplant Support Network
- Youth Net

Professional groups

- Association of Clinical Microbiologists
- Association of Medical Microbiologists
- Association of Nurses in Substance Abuse
- British Association for Services to the Elderly
- British Association for the Study of the Liver
- British Association for the Study of the Liver Nurses Forum
- British Association of Sexual Health and HIV
- British Geriatrics Society
- British Liver Nurses Forum
- British Society of Blood & Marrow Transplantation
- British Society of Gastroenterology
- British Transplantation Society
- Haemophilia Nurses Association
- Health Protection Agency
- Hepatitis Nurse Specialist Forum
- Infection Control Nurses Association
- Medical Foundation for AIDS & Sexual Health
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine Intellectual Disabilities Forum
- Society for General Microbiology
- UK Clinical Virology Network
- UK Haemophilia Centre Doctors' Organisation

- NHS Purchasing and Supply Agency
- NHS Quality Improvement Scotland
- Scottish Medicines Consortium

Comparator manufacturer(s)

- Schering-Plough (interferon alfa 2a, interferon alfa 2b)
- Novartis Pharmaceuticals UK (telbivudine)

Relevant research groups

- Foundation for Liver Research
- MRC Clinical Trials Unit
- National Institute for Health Research
- Policy Research Institute on Ageing and Ethnicity
- UCL Centre for Sexual Health & HIV Research
- United Kingdom Clinical Research Network

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

• tbc

Associated Public Health Groups

• tbc

 United Kingdom Clinical Pharmacy Association 	
Others Department of Health Western Cheshire PCT Barnet PCT Welsh Assembly Government	